IGI Logo

Alembic Pharmaceuticals is currently trading at Rs. 784.40, up by 2.65 points or 0.34% from its previous closing of Rs. 781.75 on the BSE.

The scrip opened at Rs. 790.00 and has touched a high and low of Rs. 790.00 and Rs. 780.60 respectively. So far 2128 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1090.00 on 27-Apr-2021 and a 52 week low of Rs. 672.00 on 22-Feb-2022.

Last one week high and low of the scrip stood at Rs. 790.00 and Rs. 745.00 respectively. The current market cap of the company is Rs. 15452.81 crore.

The promoters holding in the company stood at 69.61%, while Institutions and Non-Institutions held 17.76% and 12.63% respectively.

Alembic Pharmaceuticals’ wholly owned subsidiary -- Aleor Dermaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Clobetasol Propionate Foam, 0.05%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Olux Foam, 0.05%, of Mylan Pharmaceuticals Inc.

Clobetasol Propionate Foam is a corticosteroid indicated for treatment of moderate to severe plaque psoriasis of the scalp and mild to moderate plaque psoriasis of non-scalp regions of the body excluding the face and intertriginous areas in patients 12 years and Older. Clobetasol Propionate Foam, 0.05% has an estimated market size of $10 million for twelve months ending December 2021.

The company has received a cumulative total of 165 ANDA approvals (141 final approvals and 24 tentative approvals) from USFDA.

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.